Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapie for the treatment of metabolic ...

Q2 2026 Earnings Call February 26, 2026 6:00 PM ESTCompany ParticipantsKaren Borg - Co-CEO & Executive DirectorYe-Fei Guo ...

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full ...

Building a Cross-Border and Interdisciplinary Innovation Network Covering 26 Institutions Worldwide The 3rd Global Sportswear Design Award has achieved a significant transformation in its ...

Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full ...

Indivior Pharmaceuticals, Inc. ( INDV) Q4 2025 Earnings Call February 26, 2026 8:00 AM EST Good morning, everyone. I am joined today by Joe Ciaffoni, Chief Executive Officer; Pat Barry, Chief ...

Exceeds Mid-Point of Guidance Activity on Acreage Remains Robust with 85 Active Rigs Drilling Representing 16%(1) Market Share of U.S. Land Rig Count Superior Five-Year Annual Average PDP Decline Rate ...

Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise- Achieved $154.9 Million in 2025 Net Revenue- Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 ...

Good morning, and thank you for joining us today to discuss Vistance Networks, Inc. 2025 Full Year and Fourth Quarter Results. I am Jenny Thompson, Vice President of Investor Relations for Vistance ...

Geron Corporation (NASDAQ:GERN) Q4 2025 Earnings Call Transcript February 25, 2026 Geron Corporation misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.03. Operator: ...

Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its fourth quarter and full year 2025 financial results and recent business activities. Participants ...

EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clinically meaningful placebo-adjus ...